271 related articles for article (PubMed ID: 12821546)
1. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: the Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial.
Stankovic G; Colombo A; Presbitero P; van den Branden F; Inglese L; Cernigliaro C; Niccoli L; Bartorelli AL; Rubartelli P; Reifart N; Heyndrickx GR; Saunamäki K; Morice MC; Sgura FA; Di Mario C;
Circulation; 2003 Jul; 108(1):37-42. PubMed ID: 12821546
[TBL] [Abstract][Full Text] [Related]
2. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
[TBL] [Abstract][Full Text] [Related]
3. Failure of the Symbiot PTFE-covered stent to reduce distal embolization during percutaneous coronary intervention in saphenous vein grafts.
Blackman DJ; Choudhury RP; Banning AP; Channon KM
J Invasive Cardiol; 2005 Nov; 17(11):609-12. PubMed ID: 16264208
[TBL] [Abstract][Full Text] [Related]
4. Results of the Jostent coronary stent graft implantation in various clinical settings: procedural and follow-up results.
Gercken U; Lansky AJ; Buellesfeld L; Desai K; Badereldin M; Mueller R; Selbach G; Leon MB; Grube E
Catheter Cardiovasc Interv; 2002 Jul; 56(3):353-60. PubMed ID: 12112888
[TBL] [Abstract][Full Text] [Related]
5. 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial.
Stone GW; Goldberg S; O'Shaughnessy C; Midei M; Siegel RM; Cristea E; Dangas G; Lansky AJ; Mehran R
JACC Cardiovasc Interv; 2011 Mar; 4(3):300-9. PubMed ID: 21435608
[TBL] [Abstract][Full Text] [Related]
6. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts.
Gioia G; Benassi A; Mohendra R; Chowdhury K; Masood I; Matthai W
Catheter Cardiovasc Interv; 2008 Jul; 72(1):13-20. PubMed ID: 18561143
[TBL] [Abstract][Full Text] [Related]
7. Arterial versus venous bypass grafts in patients with in-stent restenosis.
Gaudino M; Cellini C; Pragliola C; Trani C; Burzotta F; Schiavoni G; Nasso G; Possati G
Circulation; 2005 Aug; 112(9 Suppl):I265-9. PubMed ID: 16159829
[TBL] [Abstract][Full Text] [Related]
8. Optimizing dosimetry with high-dose intracoronary gamma radiation (21 Gy) for patients with diffuse in-stent restenosis.
Kuchulakanti P; Torguson R; Canos D; Satler LF; Suddath W; Chan R; White LR; Gevorkian N; Bui A; Wang B; Kent KM; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2005; 6(3):108-12. PubMed ID: 16275606
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
[TBL] [Abstract][Full Text] [Related]
10. The Frontier stent registry: safety and feasibility of a novel dedicated stent for the treatment of bifurcation coronary artery lesions.
Lefèvre T; Ormiston J; Guagliumi G; Schultheiss HP; Quilliet L; Reimers B; Brunel P; Wijns W; Buettner HJ; Hartmann F; Veldhof S; Miquel K; Su X; van der Giessen WJ
J Am Coll Cardiol; 2005 Aug; 46(4):592-8. PubMed ID: 16098421
[TBL] [Abstract][Full Text] [Related]
11. Saphenous vein graft disease treated with the Wiktor Hepamed stent: procedural outcome, in-hospital complications and six-month angiographic follow-up.
Van Langenhove G; Vermeersch P; Serrano P; Kutryk MJ; Stockman D; Convens C; Van den Branden F; Vanagt E; Albertal M; Van den Heuvel P
Can J Cardiol; 2000 Apr; 16(4):473-80. PubMed ID: 10787462
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
13. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: the Asian Pacific Multicenter Arthos Stent Study (PASS) trial.
Kim YH; Lee CW; Hong MK; Park SW; Tahk SJ; Yang JY; Saito S; Santoso T; Quan L; Ge J; Weissman NJ; Lansky AJ; Mintz GS; Park SJ
Am Heart J; 2005 Feb; 149(2):336-41. PubMed ID: 15846274
[TBL] [Abstract][Full Text] [Related]
15. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions.
Jeger RV; Schneiter S; Kaiser C; Bonetti PO; Brunner-La Rocca H; Handke M; Osswald S; Buser PT; Pfisterer ME;
Cardiology; 2009; 112(1):49-55. PubMed ID: 18580059
[TBL] [Abstract][Full Text] [Related]
16. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results.
Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL
Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205
[TBL] [Abstract][Full Text] [Related]
17. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era.
Pucelikova T; Mehran R; Kirtane AJ; Kim YH; Fahy M; Weisz G; Lansky AJ; Moussa I; Gray WA; Collins MB; Kodali SK; Stone GW; Moses JW; Leon MB; Dangas G
Am J Cardiol; 2008 Jan; 101(1):63-8. PubMed ID: 18157967
[TBL] [Abstract][Full Text] [Related]
18. Comparison of stainless steel stents coated with turbostratic carbon and uncoated stents for percutaneous coronary interventions.
Haase J; Störger H; Hofmann M; Schwarz CE; Reinemer H; Schwarz F
J Invasive Cardiol; 2003 Oct; 15(10):562-5. PubMed ID: 14519887
[TBL] [Abstract][Full Text] [Related]
19. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease.
Minutello RM; Bhagan S; Sharma A; Slotwiner AJ; Feldman DN; Cuomo LJ; Wong SC
J Interv Cardiol; 2007 Dec; 20(6):458-65. PubMed ID: 18042050
[TBL] [Abstract][Full Text] [Related]
20. Clinical follow-up of paclitaxel-eluting (TAXUS) stents for the treatment of saphenous vein graft disease.
Ruchin PE; Faddy SC; Muller DW; Baron DW; Roy PR; Wilson SH
J Interv Cardiol; 2007 Aug; 20(4):258-64. PubMed ID: 17680855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
